Another early winner picked by TEDCO’s Maryland Investment Initiative, this JHU-spinout continues to focus on its mission to treat vision loss
Baltimore biopharmaceutical company AsclepiX Therapeutics Inc. is developing therapies to target eye diseases.
LEARN MORE